You are here

A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R42AI132047-03
Agency Tracking Number: R42AI132047
Amount: $1,000,000.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA21-262
Timeline
Solicitation Year: 2021
Award Year: 2023
Award Start Date (Proposal Award Date): 2023-03-01
Award End Date (Contract End Date): 2026-02-28
Small Business Information
CELDARA MEDICAL, LLC
Lebanon, NH 03766-1441
United States
DUNS: 828763263
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JOANA MURAD
 (617) 320-8521
 jm@celdaramedical.com
Business Contact
 JAKE REDER
Phone: (617) 320-8521
Email: jr@celdaramedical.com
Research Institution
 UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
 
85 SOUTH PROSPECT STREET
BURLINGTON, VT 05405-1704
United States

 Nonprofit College or University
Abstract

PROJECT SUMMARY
Rodent-borne viral outbreaks are increasing in both frequency and impact. As weather patterns evolve, rodent
populations are affected and may multiply in areas where increased contact with humans results in infection.
Hantaviruses, including Andes (ANDV) and Sin Nombre (SNV), are transmitted through the excreta of infected
rodents and, when aerosolized, infect humans. In the Americas, hantavirus infection leads to hantavirus
cardiopulmonary syndrome (HCPS), a devastating condition that features rapid onset of pulmonary edema,
respiratory failure and cardiogenic shock. Treatment is supportive, not pathogen-targeted, and accordingly,
approximately 40% of patients do not survive. Because hantaviruses establish lifelong, asymptomatic
infections in their rodent reservoirs, they are highly prevalent in nature and represent a constant threat to
humans. For example, SNV is carried by the most abundant mammal in North America, the deer mouse, which
has a near ubiquitous distribution throughout the US and Canada. In the case of the South American ANDV, in
addition to rodent-to-human transmission, human-to-human transmission occurs, putting not only the patient,
but also family members and health care workers at risk. Despite this large potential for infection and the high
case fatality rate, there are no FDA-approved treatment options or vaccines available. Hantaviruses are thus
classified as NIAID Priority Pathogens and considered potential bioterrorism threats. Our long term goal is to
develop an effective therapeutic against HCPS-causing hantaviruses.
This proposal seeks to develop human neutralizing antibodies for therapeutic and/or prophylactic treatment of
HCPS caused by ANDV. We have assembled a multidisciplinary team of molecular virologists, clinicians, and
industry partners with experience developing antibody-based therapeutics. The successful development of a
potent neutralizing antibody against ANDV has the potential to be a first-line antiviral for the treatment or
prevention of HCPS.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government